Kristen Pierce - Oct 1, 2024 Form 3/A - Amendment Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)

Role: Chief Development Officer
Signature: /s/ Chris Ehrlich, attorney-in-fact
Stock symbol: CERO
Transactions as of: Oct 1, 2024
Transactions value $: $0
Form type: 3/A - Amendment
Date filed: 5/8/2025, 06:11 AM
Date Of Original Report: Oct 2, 2024
Next filing: Jun 2, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Pierce Kristen	Chief Development Officer	CERO THERAPEUTICS HOLDINGS, INC., 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO	/s/ Chris Ehrlich, attorney-in-fact	2025-05-08	0002039649

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CERO	Stock Option (Right to Buy)							Oct 1, 2024	Common Stock	659	$10.00	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares underlying this option vest and become exercisable in twelve equal monthly installments following April 1, 2024, subject to the Reporting Person's continued service on each such vesting date.
F2	Information has been retroactively adjusted to reflect the 100-to-1 reverse stock split effected by CERo Therapeutics Holdings, Inc. on January 8, 2025.

Remarks:

This amendment to the Form 3 originally filed on October 2, 2024 is being filed solely to include a grant of employee stock options that was inadvertently omitted from the original filing.